3-methyltoxoflavin

About Collaborations Pharmaceuticals

Collaborations Pharmaceuticals applies a unique dual model of developing its own therapeutic pipeline while licensing its AI/ML software tools to external partners. The company has demonstrated success in securing non-dilutive government funding, primarily from the NIH and DOD, to advance its programs. Its most advanced asset is an enzyme replacement therapy for the ultra-rare, fatal CLN1 Batten disease, which has completed GMP manufacturing and is preparing for IND-enabling studies. The company's strategy combines internal R&D with a fee-for-service and software licensing business to fund its operations.

Therapeutic Areas